Analyzing Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Fulcrum Therapeutics (NASDAQ:FULC)

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Valuation & Earnings

This table compares Lakefront Biotherapeutics American Depositary Shares and Fulcrum Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.49	$363.05 million	($1.41)	-20.21
Fulcrum Therapeutics	$80.00 million	3.67	-$74.88 million	($1.21)	-3.18

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Fulcrum Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Lakefront Biotherapeutics American Depositary Shares and Fulcrum Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	7	1	1	2.33
Fulcrum Therapeutics	4	7	1	0	1.75

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $30.67, suggesting a potential upside of 7.64%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 112.99%. Given Fulcrum Therapeutics’ higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Fulcrum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

Risk and Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500.

Insider & Institutional Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Fulcrum Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 7 of the 13 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.